| 1 |
35250023 | Retracted: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. | 2022 Mar 7 |
1 |
| 2 |
35489723 | Regulation of Expression of Sterol Regulatory Element-binding Protein 1 in Thyroid Cancer Cells. | 2022 May |
1 |
| 3 |
34831012 | MAPK Inhibition Requires Active RAC1 Signaling to Effectively Improve Iodide Uptake by Thyroid Follicular Cells. | 2021 Nov 22 |
1 |
| 4 |
32181767 | [vestigation of molecular factors determining BRAF-inhibitor sensitivity in solid tumors]. | 2020 Mar 17 |
1 |
| 5 |
32880495 | Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation. | 2020 Nov |
1 |
| 6 |
33081092 | Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations. | 2020 Oct 16 |
2 |
| 7 |
30579838 | Schedule-dependent synergistic effects of 5-fluorouracil and selumetinib in KRAS or BRAF mutant colon cancer models. | 2019 Feb |
2 |
| 8 |
30847387 | MAPK Inhibitors Enhance HDAC Inhibitor-Induced Redifferentiation in Papillary Thyroid Cancer Cells Harboring BRAF V600E: An In Vitro Study. | 2019 Mar 29 |
2 |
| 9 |
31502118 | Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion. | 2019 Oct |
1 |
| 10 |
29737325 | The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. | 2018 May 8 |
1 |
| 11 |
27813079 | The plasma membrane Ca2+ pump PMCA4b inhibits the migratory and metastatic activity of BRAF mutant melanoma cells. | 2017 Jun 15 |
1 |
| 12 |
29040023 | Dramatic clinical and radiographic response to BRAF inhibition in a patient with progressive disseminated optic pathway glioma refractory to MEK inhibition. | 2017 May |
1 |
| 13 |
25385055 | Selumetinib for the treatment of cancer. | 2015 Jan |
1 |
| 14 |
25981859 | Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma. | 2015 Oct |
2 |
| 15 |
26567773 | Targeting inhibition of extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) suppresses growth and angiogenesis of gastric cancer. | 2015 Nov 16 |
1 |
| 16 |
26672083 | CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition Redux. | 2015 Dec 15 |
1 |
| 17 |
24200969 | Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells. | 2014 |
2 |
| 18 |
24567366 | DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. | 2014 May |
1 |
| 19 |
25199829 | RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. | 2014 Sep 11 |
1 |
| 20 |
25297634 | Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1α and oxidative phosphorylation in melanoma. | 2014 Dec 1 |
1 |
| 21 |
22972589 | Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. | 2013 Feb 15 |
3 |
| 22 |
23234544 | The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance. | 2013 Mar 1 |
1 |
| 23 |
23406027 | Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. | 2013 Feb 14 |
1 |
| 24 |
23444215 | Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. | 2013 Apr 15 |
1 |
| 25 |
23735514 | Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. | 2013 Jul |
3 |
| 26 |
23847359 | Selumetinib increases the efficacy of first-line dacarbazine. | 2013 Jul |
1 |
| 27 |
22048237 | Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. | 2012 Jan 15 |
2 |
| 28 |
22293660 | A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244). | 2012 Aug |
2 |
| 29 |
22394161 | Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma. | 2012 Apr |
1 |
| 30 |
22451620 | In search of a real "targeted" therapy for thyroid cancer. | 2012 Apr 1 |
1 |
| 31 |
22808163 | Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. | 2012 |
1 |
| 32 |
22895053 | Regulating the response to targeted MEK inhibition in melanoma: enhancing apoptosis in NRAS- and BRAF-mutant melanoma cells with Wnt/β-catenin activation. | 2012 Oct 15 |
2 |
| 33 |
21447798 | Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. | 2011 Mar 29 |
4 |
| 34 |
21674991 | A correction to the research article titled: "Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells" by A. S. Little, K. Balmanno, M. J. Sale, S. Newman, J. R. Dry, M. Hampson, P. A. W. Edwards, P. D. Smith, S. J. Cook. | 2011 |
3 |
| 35 |
21828154 | Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy. | 2011 Sep 14 |
2 |
| 36 |
20802351 | A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. | 2010 Oct |
1 |
| 37 |
20806365 | Initial testing (stage 1) of AZD6244 (ARRY-142886) by the Pediatric Preclinical Testing Program. | 2010 Oct |
1 |
| 38 |
20959481 | Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. | 2010 Nov 1 |
3 |
| 39 |
21098728 | BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. | 2010 Nov 23 |
5 |
| 40 |
19637312 | Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. | 2009 Nov 15 |
2 |
| 41 |
19861964 | Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study. | 2009 Nov 17 |
1 |
| 42 |
19915144 | MEK1 mutations confer resistance to MEK and B-RAF inhibition. | 2009 Dec 1 |
1 |
| 43 |
18381570 | BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. | 2008 Jun |
1 |
| 44 |
18676837 | BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. | 2008 Aug 1 |
5 |
| 45 |
17699718 | AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. | 2007 Aug |
1 |
| 46 |
17878251 | Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. | 2007 Dec |
1 |